Dr. Rebecca Adams -- Pharmaceutical Payment Report

This page provides a comprehensive transparency report for Dr. Rebecca Adams, a Oncology physician based in City, CO. All payment data is sourced from the CMS Open Payments (Sunshine Act) database. Dr. Rebecca Adams has received $6,624.73 in total pharmaceutical industry payments across 1 transactions from 1 pharmaceutical companies.

Physician Profile

The following profile information is sourced from the National Provider Identifier (NPI) registry and CMS Open Payments records.

Payment Summary

Dr. Rebecca Adams has received a total of $6,624.73 in pharmaceutical industry payments across 1 recorded transactions in the CMS Open Payments database. The average payment amount is $6,624.73 per transaction.

Payment Breakdown by Category

The following table shows how Dr. Rebecca Adams's pharmaceutical payments break down by payment category. Understanding the mix of payment types provides important context about the nature of the doctor-pharma relationship.

Payment CategoryAmountDescription
Consulting Fees$6,624.73Advisory board participation, clinical consulting, and expert opinion services

The largest payment category for Dr. Rebecca Adams is Consulting Fees, accounting for 100% ($6,624.73) of total pharmaceutical payments received. This suggests active involvement in pharmaceutical company advisory and educational programs.

Pharmaceutical Company Relationships

The following pharmaceutical and medical device companies have made payments to Dr. Rebecca Adams. Click on any company name to view their full physician payment profile and spending patterns.

CompanyTotal PaidTransactions
Gilead Sciences$6,624.731

Dr. Rebecca Adams has a financial relationship with Gilead Sciences, receiving $6,624.73 in total. Having a single pharmaceutical company relationship means all payments come from one source, which may indicate a focused consulting or research relationship.

Drugs and Medical Devices Referenced in Payments

The following drugs and medical devices have been referenced in pharmaceutical payments to Dr. Rebecca Adams. These references indicate that the payment was related to the marketing, consulting, or clinical use of these products.

The presence of a drug or device in a payment record means the pharmaceutical company associated the payment with that product. This is common for consulting fees related to a specific medication, speaking engagements about a product, or research involving a particular drug or device.

AI Transparency Analysis

The following analysis was generated by artificial intelligence based on Dr. Rebecca Adams's payment history, specialty peer comparisons, and payment pattern analysis. This analysis is not medical or legal advice.

Rebecca Adams has received $6.6K across 1 pharmaceutical payments as a Oncology physician in City, CO. Top paying companies include Gilead Sciences ($6.6K). The physician received a single payment of $6,625 in 2026. This payment was from Gilead Sciences and categorized as consulting. The payment is associated with the drug Skyrizi.

Patient Guidance: Questions to Ask Your Doctor

If Dr. Rebecca Adams is your physician, here is practical guidance on how to understand and discuss pharmaceutical industry relationships:

Patients may wish to inquire about any potential conflicts of interest or how these payments might influence treatment decisions, though this is a single, disclosed payment. Always feel free to ask your doctor directly about their pharmaceutical relationships.

Peer Comparison: How Dr. Rebecca Adams Compares to Other Oncology Physicians

Oncologists often engage in consulting or research with pharmaceutical companies, and this payment aligns with typical industry interactions.

Recent Payment Records

The following table shows the most recent pharmaceutical industry payments recorded for Dr. Rebecca Adams in the CMS Open Payments database. Click on any payment to view the full report.

CompanyAmountTypeDrug/DeviceDateConflict Level
Gilead Sciences$6,624.73consultingSkyrizi2026-01-02Not Assessed

Frequently Asked Questions About Dr. Rebecca Adams's Pharma Payments

Below are common questions patients ask about physician pharmaceutical payment data.

How much pharma money has Rebecca Adams received?

Rebecca Adams has received a total of $6.6K across 1 payments from pharmaceutical companies. This data is publicly reported under the CMS Open Payments (Sunshine Act) program.

Is Rebecca Adams taking too much pharma money?

Rebecca Adams has received $6.6K in pharmaceutical payments. Whether this is "too much" depends on the physician's specialty (Oncology), the types of payments, and how they compare to peers. The largest payment category is consulting ($6.6K). Payment does not imply wrongdoing, but patients should be aware and can ask their doctor directly.

What pharma companies pay Rebecca Adams?

The top pharmaceutical companies paying Rebecca Adams are: Gilead Sciences ($6.6K). These payments cover various categories including consulting, meals, speaking fees, and research grants.

What kinds of payments does Rebecca Adams receive?

Rebecca Adams's payments by type: consulting: $6.6K. Consulting fees suggest active advisory roles with pharmaceutical companies.

Should I switch doctors because of pharma payments?

Pharma payments alone are not typically reason to switch doctors. Many payments are routine (like meals at educational events) and do not indicate compromised care. Focus on: (1) whether your doctor explains treatment options clearly, (2) whether generic alternatives are discussed, (3) the overall pattern of payments, not individual transactions. If you have concerns, ask your doctor directly.

How do Rebecca Adams's payments compare to other Oncology doctors?

To compare, look at the total amount ($6.6K), number of payments (1), and the types of payments received. Oncology physicians may receive different payment amounts depending on subspecialty, geographic location, and academic affiliation. Use CMS Open Payments data to compare across the specialty.

How can I verify Rebecca Adams's payment data?

You can verify this data directly through the CMS Open Payments database at openpaymentsdata.cms.gov. Search by physician name or NPI number (1954047077). All data is reported by pharmaceutical companies and verified by CMS. DoctorPharmaData aggregates this public data for easier access.

Do pharma payments affect prescribing quality?

Research published in JAMA Internal Medicine and other peer-reviewed journals shows a statistical association between pharmaceutical payments and prescribing patterns. However, correlation does not equal causation. Many physician-industry interactions are legitimate (research, education, advisory boards). The Sunshine Act was created to promote transparency so patients can make informed decisions.

What stands out about Rebecca Adams's pharma payment profile?

The physician has a single, substantial payment, indicating a focused engagement. Rebecca Adams has received $6.6K in total pharma payments.

How does Rebecca Adams compare to peers in Oncology?

Oncologists often engage in consulting or research with pharmaceutical companies, and this payment aligns with typical industry interactions.

Are Rebecca Adams's pharma relationships typical for Oncology?

The payment is 100% concentrated with one company, Gilead Sciences.

What should patients of Rebecca Adams know about these payments?

Patients may wish to inquire about any potential conflicts of interest or how these payments might influence treatment decisions, though this is a single, disclosed payment.

What patterns are visible in Rebecca Adams's payment history?

The payment is entirely attributed to consulting services.

Understanding This Doctor Payment Report

This transparency report for Dr. Rebecca Adams is based on data from the CMS Open Payments database, which is maintained by the Centers for Medicare and Medicaid Services under the Physician Payments Sunshine Act. Here are important things to understand:

About the Physician Payments Sunshine Act

The Physician Payments Sunshine Act, enacted as Section 6002 of the Affordable Care Act in 2010, requires pharmaceutical and medical device companies to report payments and other transfers of value to physicians and teaching hospitals to CMS. This law was designed to increase transparency in the financial relationships between the healthcare industry and medical providers.

Under this law, Dr. Rebecca Adams's pharmaceutical payments are publicly disclosed. The types of reportable transactions include consulting fees, compensated speaking or educational activities, honoraria, gifts, entertainment, food and beverages, travel and lodging, education or conference attendance, research grants, charitable contributions, royalties or licenses, current or prospective ownership interests, and direct compensation for services other than consulting.

The Open Payments data for Dr. Rebecca Adams and all other physicians can be accessed at the official CMS Open Payments website.

Related Resources

Data from CMS Open Payments (Sunshine Act). Payment does not imply wrongdoing. AI analysis is not medical or legal advice. Consult your healthcare provider about any concerns.